Digital Biomanufacturing Market Opportunities and Strategies to 2034

This report describes and explains the digital biomanufacturing market and covers 2019-2024, termed the historic period, and 2024-2029, 2034F termed the forecast period. The report evaluates the market across each region and for the major economies within each region.

The global digital biomanufacturing market reached a value of nearly $21.1 billion in 2024, having grown at a compound annual growth rate (CAGR) of 11.49% since 2019. The market is expected to grow from $21.1 billion in 2024 to $40.26 billion in 2029 at a rate of 13.79%. The market is then expected to grow at a CAGR of 13.78% from 2029 and reach $76.78 billion in 2034.

Growth in the historic period resulted from the shift towards personalized medicine, expansion of the pharmaceutical industry, rising demand for biologics and growth in contract development and manufacturing organizations (CDMOs). Factors that negatively affected growth in the historic period were cybersecurity and data integrity concerns and limited awareness in developing countries.

Going forward, increasing prevalence of chronic disease, expansions of biopharmaceutical plants, rise in biosimilars production and rise in use of artificial intelligence and machine learning in healthcare will drive the growth. Factors that could hinder the growth of the digital biomanufacturing market in the future include high initial capital investment, lack of knowledge in meditech innovation and impact of trade war and tariff.

North America was the largest region in the digital biomanufacturing market, accounting for 36.47% or $7.69 billion of the total in 2024. It was followed by Asia Pacific, Western Europe and then the other regions. Going forward, the fastest-growing regions in the digital biomanufacturing market will be Asia Pacific and Western Europe where growth will be at CAGRs of 14.63% and 14.39% respectively. These will be followed by North America and Middle East where the markets are expected to grow at CAGRs of 13.48% and 13.25% respectively.

The global digital biomanufacturing market is fairly fragmented, with large number of small players operating in the market. The top ten competitors in the market made up to 20.56% of the total market in 2024. Thermo Fisher Scientific Inc. was the largest competitor with a 4.39% share of the market, followed by Danaher Corp. (Cytiva) with 3.20%, Merck KGaA with 1.93%, Dassault Systemes SE (BIOVIA) with 1.77%, Sartorius AG (Sartorius Stedim Biotech) with 1.74%, Lonza AG with 1.71%, GE Healthcare with 1.664%, Siemens AG with 1.655%, Körber Pharma (Werum PAS-X MES) with 1.28% and Agilent Technologies Inc. with 1.22%.

The digital biomanufacturing market is segmented by type into manufacturing technologies, analytical and process control technologies, software and other types. The manufacturing technologies market was the largest segment of the digital biomanufacturing market segmented by type, accounting for 41.30% or $8.71 billion of the total in 2024. Going forward, the manufacturing technologies segment is expected to be the fastest growing segment in the digital biomanufacturing market segmented by type, at a CAGR of 15.37% during 2024-2029.

The digital biomanufacturing market is segmented by types of biologic(s) manufactured into antibodies, cell and gene therapies, proteins, vaccines and other types of biologic(s) manufactured. The antibodies market was the largest segment of the digital biomanufacturing market segmented by types of biologic(s) manufactured, accounting for 49.74% or $10.49 billion of the total in 2024. Going forward, the cell and gene therapies segment is expected to be the fastest growing segment in the digital biomanufacturing market segmented by types of biologic(s) manufactured, at a CAGR of 18.23% during 2024-2029.

The digital biomanufacturing market is segmented by technology into AI and IoMT solutions, process analytical technologies, data analytics software, predictive analytics and digital twin technologies and other technologies. The AI and IoMT solutions market was the largest segment of the digital biomanufacturing market segmented by technology, accounting for 26.27% or $5.54 billion of the total in 2024. Going forward, the predictive analytics and digital twin technologies segment is expected to be the fastest growing segment in the digital biomanufacturing market segmented by technology, at a CAGR of 18.37% during 2024-2029.

The digital biomanufacturing market is segmented by application into bioprocess optimization, biomanufacturing process automation and control and other applications. The biomanufacturing process automation market was the largest segment of the digital biomanufacturing market segmented by application, accounting for 43.35% or $9.15 billion of the total in 2024. Going forward, the biomanufacturing process automation segment is expected to be the fastest growing segment in the digital biomanufacturing market segmented by application, at a CAGR of 15.40% during 2024-2029.

The digital biomanufacturing market is segmented by end user into biopharmaceutical companies, academic and research institutes and other end users. The biopharmaceutical companies market was the largest segment of the digital biomanufacturing market segmented by end user, accounting for 67.83% or $14.31 billion of the total in 2024. Going forward, the biopharmaceutical companies segment is expected to be the fastest growing segment in the digital biomanufacturing market segmented by end user, at a CAGR of 15.41% during 2024-2029.

The top opportunities in the digital biomanufacturing markets segmented by type will arise in the manufacturing technologies segment, which will gain $9.09 billion of global annual sales by 2029. The top opportunities in the digital biomanufacturing markets segmented by types of biologic(s) manufactured will arise in the antibodies segment, which will gain $9.53 billion of global annual sales by 2029. The top opportunities in the digital biomanufacturing markets segmented by technology will arise in the AI and IoMT solutions segment, which will gain $5.92 billion of global annual sales by 2029. The top opportunities in the digital biomanufacturing markets segmented by application will arise in the biomanufacturing process automation and control segment, which will gain $9.58 billion of global annual sales by 2029. The top opportunities in the digital biomanufacturing markets segmented by end user will arise in the biopharmaceutical companies segment, which will gain $15.0 billion of global annual sales by 2029. The digital biomanufacturing market size will gain the most in the USA at $6.05 billion.

Market-trend-based strategies for the digital biomanufacturing market include adoption of AI and automation for smarter bioprocessing, focus on expansion of AI-enabled biomanufacturing facilities to strengthen healthcare resilience, integration of smart sensor systems for real-time process optimization and shift toward cloud-native infrastructure for smarter biomanufacturing.

Player-adopted strategies in the digital biomanufacturing market include focus on expanding operational capabilities through new launches and partnerships.

To take advantage of the opportunities, the analyst recommends the digital biomanufacturing market companies to focus on integrating AI and ML for smarter bioprocess control, focus on integrating sensor systems for real-time bioprocess optimization, focus on adopting cloud platforms for scalable and remote biomanufacturing, focus on manufacturing technologies to maximize growth opportunities, focus on cell and gene therapies to capture high-growth potential, focus on predictive analytics and digital twin technologies to lead innovation, expand in emerging markets, focus on expanding AI-enabled facilities to strengthen biologics manufacturing, provide competitively priced offerings, focus on outcome-based pricing to reflect process efficiency gains, continue to use B2B promotions, focus on data-driven promotion to engage decision-makers and demonstrate value and focus on biomanufacturing process automation and control to maximize scalability.